Clinical review report: Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited) indication: treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support
The objective of the current CDR review was to perform a systematic review of the beneficial and harmful effects of teduglutide subcutaneous injection (Revestive) for the treatment of pediatric patients one year of age and above with Short bowel syndrome who are dependent on parenteral support
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2020, January 2020
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of the current CDR review was to perform a systematic review of the beneficial and harmful effects of teduglutide subcutaneous injection (Revestive) for the treatment of pediatric patients one year of age and above with Short bowel syndrome who are dependent on parenteral support |
|---|---|
| Physical Description: | 1 PDF file (89 pages) illustrations |